Jean-Jacques Bienaime
Independent DirectorMr. Jean-Jacques Bienaime, also known as JJ, is Non-Executive Director of Ascendis Pharma A/S from March 23, 2026. He is Member of Advisory Board of BB Biotech Ventures G.P. He is Independent Director of Incyte Corporation from January 20, 2015. He joined the Incyte Corporation on January 20, 2015. He is Independent Director of Immunome, Inc. from November 2023. He is Independent Chair of the Board of Keros Therapeutics, Inc. from August 18, 2025. He was Lead Independent Director of Keros Therapeutics, Inc. from July 1, 2024 to August 18, 2025. He was Director of Keros Therapeutics, Inc. from June 1, 2024 to July 1, 2024. He is Director of Alpha-9 Theranostics, Inc. He is Independent Director of Meliora Therapeutics, Inc. from July 2024. He was Member of Strategic Advisory Board of Longwood Fund until April 2026. He was employed at Longwood Fund until April 2026. He was Director of InterMune, Inc. He was employed at InterMune, Inc. from March 27, 2012 to September 29, 2014. He was Chairman, President & CEO of Genencor International, Inc. until April 2005. He was employed at Genencor International, Inc. from November 2002 to April 2005. He was Director of SangStat Medical Corporation. He joined the SangStat Medical Corporation in March 1999. He was Director of Ensemble Therapeutics Corporation. He was Independent Director of Portola Pharmaceuticals, Inc. He was employed at Portola Pharmaceuticals, Inc. from September 23, 2010 to June 30, 2014. He was Director of BioMarin Pharmaceutical Inc. from 2023 to May 2024. He was Chairman & CEO of BioMarin Pharmaceutical Inc. from June 2015 to December 01, 2023. He was employed at BioMarin Pharmaceutical Inc. from May 2005 to May 2024. He was Independent Director of Vital Therapies, Inc. from September 2013 to October 10, 2018. He was employed at Vital Therapies, Inc. from September 2013 to October 10, 2018. He was Director of StemCells Inc. He was President and Director of Danisco Us Inc. He was employed at Danisco Us Inc. from November 2002 to May 01, 2005. He was Lead Director of Aerogen, Inc. He joined the Aerogen, Inc. in 1999. He was Lead Independent Director of NeurogesX, Inc. He was employed at NeurogesX, Inc. from February 2004 to June 07, 2012. He was Lead Director of Saegis Pharmaceuticals, Inc. He was Chairman of the Board of Owkin, Inc. from March 2024 to 2026. He was employed at Owkin, Inc. until 2026. He has M.B.A. from University of Pennsylvania - The Wharton School, B.S. in Economics from ESCP Europe.
Positions
- Company NameIncyte CorporationStock CodeINCYPositionIndependent DirectorColleagues
- WJWilliam J. MeuryCEO & Director
- JCJulian Charles BakerIndependent Chairman of the Board
- PJPablo J. CagnoniPresident and Global Head of R&D
- TTThomas TrayPrincipal Financial Officer, VP of Finance & Chief Accounting Officer
- SHSteven H. SteinExecutive VP, Head of Late-stage Development & Chief Medical Officer
- MKMohamed Khairie IssaExecutive Vice President & Head of U.S. Commercial
- PJPaul J. ClancyIndependent Director
- JAJacqualyn A. FouseIndependent Director
- Company NameKeros Therapeutics, Inc.Stock CodeKROSPositionIndependent Chair of the BoardColleagues
- JSJasbir S. SeehraPresident, CEO & Director
- JBJean-Jacques BienaimeIndependent Chair of the Board
- ECEsther ChoChief Legal Officer & Secretary
- ATAnnita TaniniVP of Finance, Corporate Controller and Interim Principal Financial & Accounting Officer
- JFJustin FrantzHead of Investor Relations
- LLLorena LernerChief Scientific Officer
- MAMary Ann GrayIndependent Director
- AHAlpna Hansraj SethIndependent Director
- JKJulius KnowlesIndependent Director
